Stephen A. Hill

Former Director, President & Chief Executive Officer at Catalyst Biosciences, Inc.

Stephen A. Hill

Stephen A. Hill

Former Director, President & Chief Executive Officer at Catalyst Biosciences, Inc.

Overview
Career Highlights

Faraday Pharmaceuticals, Inc.
Catalyst Biosciences, Inc.
Targacept, Inc.

RelSci Relationships

660

Number of Boards

10

Birthday

1958

Age

62

Relationships
RelSci Relationships are individuals Stephen A. Hill likely has professional access to. A relationship does not necessarily indicate a personal connection.

President & Chief Executive Officer at Catalyst Biosciences, Inc.

Relationship likelihood: Strong

Founder at Faraday Pharmaceuticals, Inc.

Relationship likelihood: Strong

Executive Chairman at nLife Therapeutics SL

Relationship likelihood: Strong

Managing Director at HealthCare Ventures LLC

Relationship likelihood: Strong

Managing Director at ARCH Venture Partners

Relationship likelihood: Strong

Vice Chancellor of Innovation & Partnerships at University of California - San Francisco

Relationship likelihood: Strong

Co-Founder at Mereo BioPharma Group Plc

Relationship likelihood: Strong

President, Chief Executive Officer & Director at Cellectar BioSciences, Inc.

Relationship likelihood: Strong

Chairman of the Board, President & Chief Executive Officer at Lipocine, Inc.

Relationship likelihood: Strong

Venture Partner at ARCH Venture Partners

Relationship likelihood: Strong

Paths to Stephen A. Hill
Potential Connections via
Relationship Science
You
Stephen A. Hill
Former Director, President & Chief Executive Officer at Catalyst Biosciences, Inc.
Education

Oxford is a collegiate university, consisting of the central University and colleges. The central University is composed of academic departments and research centres, administrative departments, libraries and museums. The 38 colleges are self-governing and financially independent institutions, which are related to the central University in a federal system. There are also six permanent private halls, which were founded by different Christian denominations and which still retain their Christian character.

Memberships
Fellow
Current

The Royal College of Surgeons of England (abbreviated RCS and sometimes RCSEng), is an independent professional body and registered charity promoting and advancing standards of surgical care for patients, regulating surgery, including dentistry, in England and Wales.

Career History
President & Chief Executive Officer
2008 - 2010

Solvay Pharmaceuticals, Inc manufactures pharmaceutical products. The company produces therapies for cardi-metabolic, gastroenterological, and neurological disorders. Its brands include Androgel, Klonopin, and ACEON drugs. Solvay Pharmaceuticals was founded by Ernest Solvay in 1863 and is located in Marietta, GA.

President, Chief Executive Officer & Director
1999 - 2008

ArQule, Inc. is a biopharmaceutical company. It engages in the research and development of therapeutics to treat cancers and rare diseases. The company was founded in 1993 and is headquartered in Burlington, MA.

President & Chief Executive Officer
Prior

Unimed Pharmaceuticals, Inc. manufactured pharmaceutical products. It provided multiple indications in the therapeutic areas of cardiology, men's health, HIV and other infectious diseases. The company was founded in 1999 and was headquartered in Marietta, GA.

Boards & Committees
Chief Executive Officer & Director
2015 - Current

Faraday Pharmaceuticals, Inc. engages in the research and development of elemental reducing agents (ERAs). Its therapeutic agents have potential applications for treatment of critical care illnesses. The company was founded by Mark B. Roth and Christopher Toombs in 2014 and is headquartered in Seattle, WA.

Lead Independent Director
2014 - Current

Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development for the delivery of drugs using proprietary delivery technology. The firm involves in applying oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. It offers TLANDO, an oral testosterone replacement therapy. The company was founded in 2011 and is headquartered in Salt Lake City, UT.

Director
2007 - Current

Cellectar BioSciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma; CLR 125, which intends to treat micro metastatic disease; CLR 124 which could detects tumors and metastases in a broad range of cancers; and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded in June 1996 and is headquartered in Florham Park, NJ.

Public Holdings
Restricted data only for RelSci Professional users.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Stephen A. Hill. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Stephen A. Hill's profile does not indicate a business or promotional relationship of any kind between RelSci and Stephen A. Hill.